May 2025 – Page 11

Chronic care startup Omada Health files to go public

3 months ago talkbio0Tagged Administration occupational activities, cardiometabolic, Chronic Care Management, Diabetes, digital health, Health, Hinge Health, Hypertensive disease, IPO, musculoskeletal conditions, revenue growth, virtual care

Chronic care management, virtual care, IPO, digital health, diabetes management, cardiometabolic health, hypertension, musculoskeletal conditions, revenue growth, Hinge Health

FDA, CDC call for pause of chikungunya shot rollout in older adults

3 months ago talkbio0Tagged Adverse event, Centers for Disease Control and Prevention (U.S.), Chikungunya Fever, concerns, Elderly (population group), Ixchiq vaccine, pause recommendation, Safety, United States Food and Drug Administration

Ixchiq vaccine, chikungunya, safety concerns, older adults, FDA, CDC, pause recommendation, adverse events

Trump signs sweeping executive order to cut US drug prices by ‘up to 90%’

3 months ago talkbio0Tagged HHS, Policy, Prices, Transplant Registry Unified Management Program, United States

Prices, HHS, United States, Transplant Registry Unified Management Program, Policy

Accelerating Clinical Trial Excellence: A Seamless IRB & IBC Collaboration

3 months ago talkbio0Tagged Biosafety, Clinical Trials, Collaboration, Efficiency, Ethics Committees, Research, Homo sapiens, IBC, multi-institutional research, regulatory, research, streamlined review

Clinical trials, IRB, IBC, collaboration, streamlined review, multi-institutional research, regulatory efficiency, research acceleration, biosafety, human subject protection

AstraZeneca opens the door to Imfinzi expansion with trial win in high-risk bladder cancer patients

4 months ago talkbio0Tagged Clinical Trials, expansion, high-risk, Imfinzi, Malignant neoplasm of urinary bladder

Imfinzi, Clinical Trials, high-risk, expansion, Malignant neoplasm of urinary bladder

Sanofi axes IGM pact, sparking 80% layoffs at the biotech and facility closures

4 months ago talkbio0Tagged Biosciences, Biotech Layoffs, Collaboration termination, Facility (object), IgM antibodies, Immunoglobulin M, Immunology, Inflammation, Neoplasms, Reparative closure, sanofi

Sanofi, IGM Biosciences, collaboration termination, biotech layoffs, facility closures, IgM antibodies, immunology, inflammation, oncology

Revolutions KRAS drugs appear competitive in several lung cancer settings

4 months ago talkbio0Tagged Biological Markers, G12C inhibitors, K-ras Oncogene, KRAZATI, Lumakras, Non-Small Cell Lung Carcinoma, Rotation, sotorasib

KRAS G12C inhibitors, non-small cell lung cancer (NSCLC), targeted therapy, sotorasib (Lumakras), adagrasib (Krazati), biomarker testing, Revolution Medicines

Argenx brews up DTC push for Vyvgart Hytrulo prefilled syringe in generalized myasthenia gravis

4 months ago talkbio0Tagged Approved, DTC Campaign, Empowerment, Myasthenia Gravis, Generalized, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, self-administration, Syringes, United States Food and Drug Administration, Vyvgart Hytrulo

Vyvgart Hytrulo, prefilled syringe, FDA approval, self-administration, generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), DTC campaign, patient empowerment